Overview

A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.

Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
To explore the mechanism of action of ranolazine as a potential treatment for type 2 diabetes mellitus (T2DM).
Phase:
Phase 1
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Exenatide
Glucagon
Ranolazine